医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

SanBio: Addition of a Cerebral Hemorrhage Program for SB623 Regenerative Cell Medicine

2019年01月21日 AM09:05
このエントリーをはてなブックマークに追加


 

TOKYO

At a meeting held today, the Board of Directors of SanBio Co., Ltd. (hereinafter, the “Company”) resolved to add a program for treatment of chronic motor deficit from cerebral hemorrhage as a new indication for SB623, a regenerative cell medicine developed by the Group. (Hereinafter, the “Group” refers to two companies, SanBio Co., Ltd., and SanBio, Inc.)

1. Details of the Decision

As part of its mission to introduce new therapeutic drugs for the central nervous system, the Group is moving forward with the development of programs for chronic motor deficit from traumatic brain injury (TBI) and chronic motor deficit from ischemic stroke, centering on the United States and Japan. Regarding the program for treatment of chronic motor deficit from TBI, positive results were announced on November 1, 2018, with respect to a Phase 2 clinical trial, namely that “Patients administered SB623 demonstrated a statistically significant improvement in their motor function compared to the control group, confirming that the study has met its primary endpoint.” Regarding the program targeting chronic motor deficit from ischemic stroke, the Company expects to announce results of a Phase 2b clinical trial in the first half of the fiscal year ending January 31, 2020 (from February 1, 2019 to July 31, 2019).

Given the positive results of the program targeting chronic motor deficit from TBI mentioned above, the Group has reevaluated the scope of indications for SB623. Consequently, the Company has decided to initiate a program for treatment of chronic motor deficit from cerebral hemorrhage, which is similar to TBI, as a new indication for SB623. The Company is considering Japan and the United States as development regions for this program.

Ischemic stroke is caused by the blockage of blood vessels, whereas cerebral hemorrhage results from ruptured blood vessels. Both can result in hemiplegia, sensory impairment, or memory impairment. Currently, no definitive therapy exists.

As of today, the Company expects to commence clinical trials for this program from Phase 2 or Phase 3. However, the development details and timing are not yet decided. The Company will provide these as soon as they become available.

2. Outlook

This decision does not affect the Company’s consolidated operating performance for the fiscal year ending January 31, 2019.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190120005025/en/

CONTACT

SanBio Co., Ltd.
Yoshihiro Kakutani, Corporate Officer of
Management Administration
(TEL. +81-3-6264-3481)

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Seoul Viosys’ Violeds Modules Proven to Disinfect 99% of Airborne Viruses in a Recent Testing Result
  • Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
  • Kaye推出适用于冷链运输市场的Kaye® Log -80℃ 疫苗温度记录器,以满足COVID-19疫苗储存和运输的要求
  • Kaye® (ケイ)は、COVID-19ワクチンの輸送・保管のニーズに応えるためにKaye® ログ -80ワクチン温度ロガーを、コールドチェーン市場向けに導入(発売)します。
  • DNP的新型非接触式透明屏幕可通过手的动作进行操作